In response to the FDA’s historic decision, the Drug Enforcement Administration (DEA) announced in September 2018 that it had removed Epidiolex from Schedule I classification, a category reserved for dangerous drugs with no medical value. Henceforth, Epidiolex would be considered a Schedule V drug, the least dangerous designation under the Controlled Substances Act.
For example, 100mg of isolated CBD may be substantially less effective at alleviating symptoms than 100mg of a whole-plant, cannabis extract that contains CBD. While it may be cheaper and more cost-effective to extract CBD from industrial hemp, users may ultimately experience less benefit due to the absence of clinically significant levels of terpenes and other compounds which are plentiful in cannabis. While high-CBD cultivars of cannabis do contain much higher levels of various cannabinoids and terpenes, there are risks and side effects associated with its use.